問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Hematology & Oncology

更新時間：2025-08-20

蔡承志
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

14Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

蔡承志

List

16Cases

2025-06-01 - 2028-05-31

Phase III

Not yet recruiting
A Phase 3, Randomized, Multicenter, Parallel-arm, Double-blind Study to Compare Efficacy and Safety of EG1206A (EirGenix' Pertuzumab) and Perjeta® (Pertuzumab) Sourced From EU as Neoadjuvant Treatment in Combination With Trastuzumab and Chemotherapy in Patients With HER2-positive Hormone Receptor-negative Early Breast Cancer

  • Condition/Disease

    Early Breast Cancer

  • Test Drug

    Injectable solution

Participate Sites
11Sites

Recruiting11Sites

2025-06-06 - 2028-09-13

Phase III

Active
VIKTORIA-2: A Randomized, Open-Label, Phase 3 Study of Fulvestrant and CDK4/6 Inhibitors With or Without Gedatolisib as First-Line Treatment in Patients With HR-Positive and HER2-Negative Advanced Breast Cancer

  • Condition/Disease

    Breast Cancer

  • Test Drug

    Infusion fluid

Participate Sites
7Sites

Recruiting7Sites

2024-04-01 - 2028-01-31

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting1Sites

Recruiting9Sites

2024-07-31 - 2031-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2026-04-01 - 2029-11-30

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

2025-09-01 - 2031-06-30

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2025-08-01 - 2027-11-08

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-07-07 - 2029-12-31

Phase I

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-02-28 - 2032-06-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2024-01-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB